| Description |
| Product Type |
Product Size |
| Tablets |
120'S |
| Product Company |
| Beacon Pharmaceuticals |
Abiraterone acetate 250mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Martin Dow |
Ondansetron 8mg/4ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Pertuzumab 420mg/14ml |
| Product Type |
Product Size |
| Tablet |
10'S |
| Product Company |
| Martin Dow |
Ondansetron 8mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmasol |
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Searle Pharma |
|
| Content | Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer. | Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Ondansetron is one of the medications most commonly used for the empiric treatment of nausea and vomiting. Ondansetron has excellent utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. | Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. So, it stops the growth of the cancer. | Rituximab, an anti CD20 monoclonal antibody, is used in the management of lymphoproliferative and autoimmune conditions. |
Reviews
There are no reviews yet.